Objectives: Laboratory services are an important part of the healthcare system. However many requested tests may be considered inappropriate or unnecessary. We evaluated laboratory use in a period of 3 years in terms of the inappropriate test repeats. Methods: We analyzed inappropriate repeat rate (IRR) of hemoglobin A1c (HbA1c), 25-OH vitamin D [25(OH)D], thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase antibody (anti-TPO), vitamin B12, folate, iron, ferritin and total cholesterol in the light of clinical guidelines. Results: IRR of 3 year was found to be 10% on average (4.2–15.5%). In TSH, FT3, and FT4 parameters, IRR was between 4.2 and 5.3%, while it was between 12.9 and 15.5% for 25(OH)D, iron, ferritin, and total cholesterol. In all tests (except anti-TPO), IRRs were found to be higher in inpatients for each of the 3 years. Inappropriate repetition of total cholesterol, iron, and ferritin parameters were more frequent in men. Inappropriate repeats were performed in all parameters (except HbA1c) after a result that had been in the reference range. Conclusions: Examined test repetitions were mostly inappropriate. To reduce the inappropriate laboratory test requests, it is important to analyze the causes and to ensure cooperation between laboratory specialists and clinicians.
Kardiyovasküler Hastalık Risk Hesaplama Sistemleri ve Yeni Bir Model: Prevent Makbule Beyza ŞEN Yasemin ATICI Doğan YÜCEL Tek Karbon Metabolizmasında Vitamin B12 ve Folatın Rolü Ayşenur MACUN AYAN Klinik Laboratuvarlar İçin Metot Verifikasyonu Levent DENİZ Lipoprotein (a): Kardiyovasküler Risk Değerlendirmesinde Kritik Bir Lipoprotein Zeynep Mine YALÇINKAYA KARA Parkinson, Alzheimer ve ALS Gibi Hastalıklarda Mitokondriyal Fonksiyon Bozukluklarının Enerji Üretimindeki Aksamaları Naci Ömer ALAYUNT İnterlökin-22 ve Klinik Önemi Arzu YÜKSEL Lipokinler Merve Sena ODABAŞI Sarı Kantaronun İnsan Sağlığına Etkisi ve Tıp Alanında Kullanım Potansiyeli Murat ÇAKIR Kültür Eti Üretimi ve Özellikleri Adile Merve BAKI
15 October 2019 in Turkish Journal of Biochemistry
Background: It is responsibility of medical laboratories to determine and reject nonconforming samples as well as take preventive actions. In this study, we examined reasons and percentages of rejected samples. We also investigated impact of the preventive actions on decreasing the rejection rates. Materials and methods: Reasons for rejection were determined by Pareto analysis. Sigma analysis was used for each month to evaluate the ratios and compare with other studies. Some preventive actions were taken to reduce the rejection rates. Pearson’s chi square test was used to evaluate effects of preventive actions. Significance level was determined as p < 0.05. Results: Most of the rejected samples consisted of samples not received by the laboratory, haemolysed and insufficient samples. The percentages of samples not received by the laboratory and insufficient samples were reduced from 3.80% to 1.94% and 0.33% to 0.31% respectively, while haemolysed samples percentage was increased from 2.83% to 3.37% after the improvement actions. Also, sigma levels for samples not received by the laboratory and haemolysed samples were at the minimum while insufficient samples were at a reasonable level. Conclusion: Improvement actions achieved statistically significant decreases for samples not received by the laboratories for a long-term.
The icteric index (I-index) is a practical and low-cost method for screening hyperbilirubinemia and potentially reducing unnecessary total bilirubin (TBil) testing. This study was designed to determine a safe I-index to detect TBil above the upper reference range to avoid unnecessary TBil orders. The reflexive addition of TBil in samples where I-index is above the cut-off value and TBil measurement is not initially planned will be a secondary gain of the study. This study included 267185 samples with TBil test results and corresponding I-index values. TBil and I-index values were measured with the Roche Cobas 8000 (c701) and Cobas 6000 (c501) analyzers. Statistical analyses were performed using SPSS 15.0, with ROC curve analysis used to determine the optimal I-index cut-off for TBil screening. An I-index cut-off of 34.2 μmol/L provided the lowest false negativity (0.45 %), highest specificity (97.1 %), and negative predictive value (99.5 %). Using this cut-off point, if we had reached 100 % NPV, 87.4 % of TBil tests in the group receiving inpatient/outpatient treatment with Cobas-8000 and 89.8 % in the emergency group with Cobas 6000 could have been saved. This is the study with the largest sample size. The sample size is critical in determining a reliable I-index cut-off point. We conclude that I-index should not replace TBil since the NPV was not 100 %; however, it seems reasonable to reflexively add TBil testing in samples where the I-index is above the cut-off value and TBil measurement was not initially planned.